| Literature DB >> 30406114 |
Maedeh Zamani1,2, Esra Karaca1,2,3, Ngan F Huang1,2,3.
Abstract
Cardiovascular disease is a leading cause of death in the US and many countries worldwide. Current cell-based clinical trials to restore cardiomyocyte (CM) health by local delivery of cells have shown only moderate benefit in improving cardiac pumping capacity. CMs have highly organized physiological structure and interact dynamically with non-CM populations, including endothelial cells and fibroblasts. Within engineered myocardial tissue, non-CM populations play an important role in CM survival and function, in part by secreting paracrine factors and cell-cell interactions. In this review, we summarize the progress of engineering myocardial tissue with pre-formed physiological multicellular organization, and present the challenges toward clinical translation.Entities:
Keywords: cardiomyocyte; cardiovascular tissue engineering; co-culture; endothelial cell; engineered myocardium; fibroblast; stem cell
Year: 2018 PMID: 30406114 PMCID: PMC6205951 DOI: 10.3389/fcvm.2018.00147
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Multicellularity of the myocardial environment. Cardiomyocytes interact with support cells such as endothelial cells and fibroblasts to maintain their cell function. The underlying extracellular matrix also provides instructive cues that regulate cell survival and function.